Examining the link between adiponectin levels and heart and brain diseases in Chinese individuals
Serum Adiponectin Concentration, Activity and Isoforms in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases
This study looks at whether levels of a protein called adiponectin can help predict the risk of heart and brain diseases in Chinese individuals over five years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30000 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Xijing Hospital Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT01372800 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the concentration, activity, and isoforms of serum adiponectin in a Chinese population over a five-year follow-up period. It aims to establish correlations between adiponectin levels and the incidence of myocardial and cerebral infarctions. The study focuses on understanding how adiponectin, a protein with anti-inflammatory and vascular protective properties, may serve as a novel risk factor for cardiovascular and cerebrovascular diseases. Participants will be monitored for changes in their health related to these conditions throughout the study duration.
Who should consider this trial
Good fit: Ideal candidates for this study are Chinese individuals who can commit to a five-year follow-up and do not have conditions that would interfere with the study.
Not a fit: Patients who have conditions unrelated to cardiovascular or cerebrovascular diseases, or those who are pregnant or have severe renal or hepatic dysfunction, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into adiponectin as a potential biomarker for cardiovascular and cerebrovascular diseases, leading to improved risk assessment and management strategies.
How similar studies have performed: Other studies have indicated a correlation between adiponectin levels and cardiovascular diseases, suggesting that this approach has been explored with some success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * available for 5 years of follow-up study Exclusion Criteria: * Death caused other than cardiovascular and cerebralvascular diseases till the study ends * Floating Population * Pregnancy, lactation, or child bearing women * Tumor * Active hepatic disease or hepatic dysfunction, or AST/ALT \> 1.5UNL * Severe renal dysfunction(Scr \> 3 mg/dl or 264μmol/L) * Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding
Where this trial is running
Xi'an, Shaanxi
- Xijing Hospital — Xi'an, Shaanxi, China (Recruiting)
Study contacts
- Study coordinator: Ling Tao, M.D Ph.D
- Email: lingtao2006@gmail.com
- Phone: +86-15002955798
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.